Celsius Holdings is caught between three conflicting forces: short sellers who have doubled down aggressively over six weeks, a CEO who opened his own wallet near the lows, and options traders who remain stubbornly bullish despite the bearish positioning overhead.
The short side of this trade has built fast. Short interest now stands at 14.3% of free float — up 53% over the past month and 18% in the past week alone, reaching roughly 36.8 million shares. That monthly pace of accumulation is striking. Where the previous note flagged availability compressing toward 108%, it has since eased modestly to 116%, suggesting the immediate squeeze on borrow supply has stabilised rather than intensified. Cost to borrow, at 0.60%, remains low in absolute terms despite rising 24% over the week — bears are not paying a punishing rate to hold their positions. The ORTEX short score of 69.3 is fractionally off its recent peak of 69.8 but still elevated, ranking in the bottom 5th percentile of the universe for short pressure. Put differently, one stock in twenty has heavier short positioning than CELH right now.
Options traders are not buying the bear case. The put/call ratio has dropped to 0.40 — nearly two standard deviations below its 20-day average — approaching the lowest reading of the past year. Call volume is running well ahead of puts. The stock's 6.5% weekly gain and 4.4% single-day move on June 16 have done nothing to shake that bullish options tilt. What is notable is that insiders leaned in around the same price level. CEO John Fieldly bought 8,475 shares at $29.36 on May 22, the President/COO added 7,500 shares at $29.04 the day before, and the Lead Independent Director took 8,400 shares at $29.73 the same day as Fieldly. Those three purchases totalling roughly $716,000 clustered within 48 hours at prices near where the stock had been drifting for weeks. Net insider buying over the trailing 90 days is positive at approximately $1.3 million, though that figure includes some smaller routine sales from the CFO and COO afterward.
The Street consensus is unambiguously constructive, even if targets have been drifting lower. Thirteen analysts carry buy-equivalent ratings with a mean price target near $60 — roughly double the current price of $30. Bernstein initiated coverage this week with an Outperform and a $44 target, the freshest data point. JPMorgan raised its target to $70 after the last earnings print, while Morgan Stanley trimmed to $55 and BNP Paribas cut to $57 from $70 — both maintaining positive ratings. The direction of travel on targets has been downward for months as the stock de-rated, but no major house has moved to the sidelines. Valuation has compressed to a PE near 16.5x and EV/EBITDA of 11.6x — a far cry from the growth multiples the stock once commanded, though the forward earnings picture remains strong: the eps_12m_fwd_yoy_increase factor ranks in the 93rd percentile. The bull case centres on Alani Nu's accelerating momentum and the PepsiCo distribution runway; the bear case is really a question of execution pace rather than structural doubt.
Earnings history adds a cautionary note on timing. The last two results prints each produced five-day losses of around 12%, even when the initial one-day reaction was mixed. The next event is scheduled for August 7. Between now and then, the tension to watch is whether the stock's bounce off the $29 level — where insiders bought — triggers short covering, or whether the bears who built 53% more exposure in a single month hold their ground and wait for the next fundamental catalyst to prove them right.
See the live data behind this article on ORTEX.
Open CELH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
